Liraglutide dose-dependently reduced urinary protein, improved kidney blood vessel function, and increased nitric oxide production in diabetic rats by inhibiting the Dll4/Notch2 signaling pathway.
Dose-dependent kidney protectionHigher doses of liraglutide produced greater reductions in urinary protein and kidney damage markers while suppressing the Dll4/Notch2 inflammatory pathway
What the researchers found
In a streptozotocin/high-fat diet diabetic rat model, liraglutide treatment produced dose-dependent improvements:
- Significant reductions in blood glucose, serum creatinine, and blood urea nitrogen (P < 0.05)
- Dose-dependent decrease in 24-hour urinary protein excretion and microalbuminuria (P < 0.05)
- Improved glomerular and interstitial damage
- Suppressed expression of endothelial injury markers CD31, CD34, and VE-cadherin (P < 0.05)
- Significantly increased nitric oxide (NO) production (P < 0.05)
- Decreased expression of VEGF, Dll4, and Notch2 protein in the Notch2 signaling pathway (P < 0.05)
- Higher doses showed more pronounced therapeutic effects
Why it matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. Understanding how GLP-1 drugs protect kidney blood vessels at the molecular level — specifically through the Dll4/Notch2 pathway — could help develop more targeted treatments and identify patients who would benefit most from GLP-1 therapy for kidney protection.
How the study worked
Diabetes was induced in rats using a high-fat/high-sugar diet combined with a single streptozotocin injection. Diabetic rats were treated with various doses of liraglutide. Kidney function was assessed by blood glucose, serum creatinine, BUN, and urinary protein. Kidney pathology was examined histologically. Endothelial markers (CD31, CD34, VE-cadherin), nitric oxide levels, and Dll4/Notch2 pathway proteins were measured.
What this study cannot tell us
This was an animal study using a chemically-induced diabetes model, which may not fully replicate human diabetic kidney disease. The specific doses may not correspond to human therapeutic levels. The study focused on early endothelial dysfunction, so effects on advanced kidney disease are unknown. The Dll4/Notch2 pathway involvement is correlational — additional studies are needed to confirm it as the primary mechanism.
How to read the evidence
This is a preclinical rat study using a standard diabetic nephropathy model. It provides mechanistic insights but cannot be directly extrapolated to human kidney outcomes. Clinical trials have separately confirmed GLP-1 drugs' kidney benefits.
When this study was published
Published in 2024, this is recent mechanistic research complementing the clinical evidence from trials like FLOW and SOUL on GLP-1 kidney protection.
The bigger picture
Clinical trials have shown that GLP-1 drugs protect the kidneys in diabetic patients, but the molecular mechanisms are still being uncovered. This study identifies the Dll4/Notch2 pathway as a specific mechanism through which liraglutide preserves kidney blood vessel health, adding to the growing understanding of how these drugs work beyond blood sugar control.
Questions still open
- Is the Dll4/Notch2 pathway involved in liraglutide's kidney-protective effects in human diabetic patients?
- Would directly targeting the Dll4/Notch2 pathway provide additional kidney protection beyond what GLP-1 drugs offer?
- Do other GLP-1 receptor agonists show the same Dll4/Notch2 pathway modulation?
Common questions
How does liraglutide protect the kidneys?
Does the dose of liraglutide matter for kidney protection?
Read the original research
Liraglutide Ameliorates Renal Endothelial Dysfunction in Diabetic Rats Through the Inhibition of the Dll4/Notch2 Pathway.
Diabetes, metabolic syndrome and obesity : targets and therapy, 17, 4091-4104
Citation
Li, Yining; Chen, Yulin; Zhang, Hui; Chen, Weidong; Pan, Yan. (2024). Liraglutide Ameliorates Renal Endothelial Dysfunction in Diabetic Rats Through the Inhibition of the Dll4/Notch2 Pathway.. Diabetes, metabolic syndrome and obesity : targets and therapy, 17, 4091-4104. https://doi.org/10.2147/DMSO.S492252